Tag Archive for: Alys Pharmaceuticals

Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic Urticaria

/in

Differentiated profile of ALY-301 designed to enable chronic dosing in mast cell dependent diseases while avoiding the safety limitations of conventional c-Kit inhibitors Multicenter Phase 1/1b study to enroll both healthy volunteers and patients with Cold Urticaria with initial data readouts expected in 2026 Boston, Massachusetts and Lausanne, Switzerland, 30 October 2025 – Alys Pharmaceuticals, […]

Read more

Weekly roundup: Innovation and deals for Optimum’s clients

/in

SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]

Read more

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata

/in

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications  ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata Health Authorities in Canada and the United States provided swift CTA & IND approval allowing for efficient dosing of the first patients Boston, Massachusetts and […]

Read more